Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 07/31/2018
Entire Document
 


In re: Orexigen Therapeutics, Inc.    Case No. 18-10518 (KG)
Debtor    Reporting Period: June 1, 2018 - June 30, 2018

MOR - 1b

Schedule of Debtor Bank Account Balances (1)

For the Period: June 1, 2018 - June 30, 2018

(Unaudited)

 

$ USD ‘000s

Debtor        

 

Bank

  Last Four Digits
Account No.
    

Account Description

  Beginning
Balance
6/1/2018
    Ending
Balance
6/30/2018
 

Orexigen Therapeutics, Inc.

  Silicon Valley Bank     6813      General checking   $ 2     $ 190  

Orexigen Therapeutics, Inc.

  Silicon Valley Bank     1180      Zero-balance lockbox     —         —    

Orexigen Therapeutics, Inc.

  Silicon Valley Bank     3036      Sweep account     17,301       15,434  

Orexigen Therapeutics, Inc.

  Silicon Valley Bank     7307      Utility adequate assurance     10       10  

Orexigen Therapeutics, Inc.

  Silicon Valley Bank     5177      Collateral     100       100  

Orexigen Therapeutics, Inc.

  U.S. Bank     4219      Investment account(2)     —         —    

Orexigen Therapeutics, Inc.

  State Street Bank & Trust     2355      Investment account(2)     —         —    

Orexigen Therapeutics, Inc.

  Wells Fargo     3348      Foreign wire transfer account(2)     —         —    

Orexigen Therapeutics, Inc.

  JMP Securities LLC     0041      Investment account(2)     —         —    
        

 

 

   

 

 

 

Total Bank Account Balances

         $ 17,413     $ 15,734  
        

 

 

   

 

 

 

Notes:

 

(1)

The Consolidated Schedule of Cash Receipts and Disbursements (MOR-1) and Schedule of Disbursements by Debtor Entity (MOR-1a) represent book balances while MOR-1b represents bank balances. The balances differ primarily due to the bank’s delayed recording of intrabank activity between the general checking and sweep accounts.

(2)

Account was closed in April 2018.